期刊文献+

风湿性多肌痛患者血清骨转化标志物水平变化及意义 被引量:1

下载PDF
导出
摘要 目的探讨风湿性多肌痛(PMR)患者血清骨转化标志物水平变化及临床意义。方法选择47例PMR患者作为观察组,47例骨关节炎患者作为对照组。收集两组病历资料,包括性别、年龄、病程、身高、体质量及实验室指标[血红蛋白(Hb)、红细胞沉降率(ESR);用电化学发光法检测两组血清骨转化标志物,包括25-羟维生素D_(3)[25-(OH)VD_(3)]、总Ⅰ型前胶原氨基端延长肽(tP1NP)、甲状旁腺激素(PTH)及I型胶原羧基端肽β特殊序列(β-CTX);用Spearman相关法分析骨转化标志物与ESR的相关性。结果与对照组比较,观察组Hb水平低,ESR水平高,血清25-(OH)VD_(3)、tP1NP水平低(P均<0.05);两组血清PTH、β-CTX水平比较差异无统计学意义(P均>0.05)。观察组血清25-(OH)VD_(3)水平与ESR水平呈负相关(r=-0.479,P<0.05),血清tP1NP水平与ESR水平无相关性(r=-0.140,P>0.05)。结论PMR患者血清25-(OH)VD_(3)、tP1NP水平低,血清25-(OH)VD_(3)水平变化与患者炎症活动有关;血清PTH、β-CTX水平无显著变化。
出处 《山东医药》 CAS 2023年第4期76-78,共3页 Shandong Medical Journal
  • 相关文献

参考文献1

二级参考文献59

  • 1刘红,廖二元,伍贤平,张红,罗湘杭,谢辉,曹行之,刘石平.正常女性与年龄相关的骨转换生化指标和骨密度的关系[J].中华内科杂志,2004,43(11):805-809. 被引量:27
  • 2邱明才,戴晨琳.代谢性骨病学[M].北京:人民卫生出版社,2012:9305.
  • 3Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. E- valuation, treatment, and prevention of vitamin D defi- ciency: an Endocrine Society clinical practice guideline [Jl- J Clin Endocrinol Metab, 2011, 96: 1911-1930.
  • 4Binkley N, Wiebe D. Clinical controversies in vitamin D: 25OHD measurement, target concentration, and supple- mentation [J]. J Clin Densitomet, 2013, 16: 402-408.
  • 5Xie Z, Zhang Z, Liao E, et al. High prevalence of vita- min D insufficiency and deficiency among postmenopausal women in China: Preliminary Results of a Chinese Multi- center Study [ C 1. The American Society for Bone and Mineral Research (ASBMR) Annual Meeting, 2014.
  • 6Wang Q, Lu C, Xu Y, et al. Prevalence of vitamin D de- ficiency in women who live with lowest sunshine: an epide- miological study in Sichuan, China [ C 1. 7th International Conference on Osteoporosis and Bone Research, 2014.
  • 7Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney Int, 2009, 113: $1-130.
  • 8Almond A, Ellis AR, Walker SW, et al. Current para- thyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease [ J]. Ann Clin Biochemist, 2012, 49: 63-67.
  • 9Liao E. FGF23 associated bone diseases [ J]. Front Med, 2013, 7: 65-80.
  • 10Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 meas- urements ~J~. J Clin Endocrinol Metab, 2012, 97: 3357-3365.

共引文献130

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部